
|Articles|September 27, 2014
- Head and Neck Cancers (Issue 2)
- Volume 2
- Issue 1
Sequencing Sorafenib and Lenvatinib in Thyroid Cancer
Author(s)Marcia S. Brose, MD, PhD, FASCO
Marcia S. Brose, MD, PhD, discusses using both sorafenib and lenvatinib as treatment options for thyroid cancer.
Advertisement
Articles in this issue
about 11 years ago
Treatment Update: Unresectable Medullary Thyroid Cancerabout 11 years ago
The Side Effects of Lenvatinibabout 11 years ago
Immune Checkpoint Inhibitors for Head and Neck Cancersabout 11 years ago
Battling the Immunosuppressive Nature of Head and Neck CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5










































